Histone deacetylase-based dual inhibitors: research progress focusing on non-small cell lung cancer therapy
RSC Medicinal Chemistry · 2026 · 17 (7) · 3168-3179
DOI: 10.1039/d6md00063k ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift RSC Medicinal Chemistry, 2026. Verfasst von Zihao Liu und 1 weiteren Autor:innen. Beteiligte Einrichtung: China-Japan Union Hospital of Jilin University Department of Thoracic Surgery Changchun Jilin 130033 China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
HDAC dual-target inhibitors integrate epigenetic modulation with complementary pathway blockade, achieving synergistic antitumor effects in NSCLC by enhancing efficacy, overcoming drug resistance, and reducing toxicity.
Autor:innen und Institutionen
- China-Japan Union Hospital of Jilin University Department of Thoracic Surgery Changchun Jilin 130033 China.
- The First Hospital of Jilin University Department of Thoracic Surgery Changchun Jilin 130021 China zgyang@jlu.edu.cn.
ORCID-Profile: Zhiguang Yang
Zitieren
APA
Liu, Z., & Yang, Z. (2026). Histone deacetylase-based dual inhibitors: research progress focusing on non-small cell lung cancer therapy. RSC Medicinal Chemistry, 17(7), 3168-3179. https://doi.org/10.1039/d6md00063k
Vancouver
Liu Z, Yang Z. Histone deacetylase-based dual inhibitors: research progress focusing on non-small cell lung cancer therapy. RSC Medicinal Chemistry. 2026;17(7):3168-3179. doi:10.1039/d6md00063k
BibTeX
@article{Liu2026,
author = {Liu, Zihao and Yang, Zhiguang},
title = {Histone deacetylase-based dual inhibitors: research progress focusing on non-small cell lung cancer therapy},
journal = {RSC Medicinal Chemistry},
year = {2026},
volume = {17},
number = {7},
pages = {3168--3179},
doi = {10.1039/d6md00063k}
}
EUVIMED